Goldman Sachs Downgrades Illumina, Waters amid Concerns over Academic and Government Spending

The downgrades to Illumina and Waters reflect larger worries the investment bank has about the end markets of life science tools firms.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.